Francesca Cossarini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6603487/publications.pdf Version: 2024-02-01

		759233	580821
29	2,144	12	25
papers	citations	h-index	g-index
31	31	31	6624
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Immunology of COVID-19: Current State of the Science. Immunity, 2020, 52, 910-941.	14.3	1,387
2	Coronavirus 2019 and People Living With Human Immunodeficiency Virus: Outcomes for Hospitalized Patients in New York City. Clinical Infectious Diseases, 2020, 71, 2933-2938.	5.8	189
3	Intestinal Host Response to SARS-CoV-2 Infection and COVID-19 Outcomes in Patients With Gastrointestinal Symptoms. Gastroenterology, 2021, 160, 2435-2450.e34.	1.3	118
4	Cross-resistance Profile of the Novel Integrase Inhibitor Dolutegravir (S/GSK1349572) Using Clonal Viral Variants Selected in Patients Failing Raltegravir. Journal of Infectious Diseases, 2011, 204, 1811-1815.	4.0	94
5	Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity. Nature Medicine, 2022, 28, 766-779.	30.7	70
6	Limited intestinal inflammation despite diarrhea, fecal viral RNA and SARS-CoV-2-specific IgA in patients with acute COVID-19. Scientific Reports, 2021, 11, 13308.	3.3	50
7	Tenâ€year survival among HIVâ€1â€infected subjects with AIDS or nonâ€AIDSâ€defining malignancies. International Journal of Cancer, 2012, 130, 2990-2996.	5.1	29
8	Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL. Journal of Antimicrobial Chemotherapy, 2012, 67, 213-217.	3.0	26
9	Durability and Safety of a Novel Salvage Therapy in R5-Tropic HIV-Infected Patients: Maraviroc, Raltegravir, Etravirine. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, e113-e115.	2.1	19
10	Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy. Aids, 2014, 28, 2407-2415.	2.2	16
11	Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients. BMC Infectious Diseases, 2017, 17, 43.	2.9	15
12	Integrase and Fusion Inhibitors Transmitted Drug Resistance in Naive Patients With Recent Diagnosis of HIV-1 Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, e51-e53.	2.1	14
13	Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens. Aids, 2012, 26, 1837-1840.	2.2	11
14	Mortality of HIV-Infected Patients with or without Cancer: Comparison with the General Population in Italy. Antiviral Therapy, 2012, 17, 447-458.	1.0	10
15	Immune recovery and T cell subset analysis during effective treatment with maraviroc. Journal of Antimicrobial Chemotherapy, 2012, 67, 2474-2478.	3.0	10
16	Missed Opportunities for HIV Prevention: Individuals Who HIV Seroconverted Despite Accessing Healthcare. AIDS and Behavior, 2018, 22, 3519-3524.	2.7	7
17	Ranolazine-induced Repolarization Changes: A Case Report. American Journal of Medicine, 2015, 128, e3-e5.	1.5	5
18	Survival of HIV-1 Infected Multidrug-Resistant Patients Recycling Enfuvirtide After a Previous Failure. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 51, 179-184.	2.1	4

#	Article	IF	CITATIONS
19	Viro-immunological dynamics in HIV-1-infected subjects receiving once-a-week emtricitabine to delay treatment change after failure: A pilot randomised trial. Journal of Clinical Virology, 2010, 47, 253-257.	3.1	4
20	Monotherapy With Atazanavir as a Simplificati Strategy. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 60, e101-e103.	2.1	4
21	The Reply. American Journal of Medicine, 2015, 128, e39.	1.5	4
22	Clinical, virologic, and immunologic outcomes in lymphoma survivors and in cancerâ€free, HIVâ€1–infected patients. Cancer, 2013, 119, 2710-2719.	4.1	3
23	Prior Therapy Influences the Efficacy of Lamivudine Monotherapy in Patients With Lamivudine-Resistant HIV-1 Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, e34-e35.	2.1	1
24	Immortal time bias. Aids, 2015, 29, 860-861.	2.2	1
25	785 SARS-COV-2 INFECTS ENTEROCYTES IN VIVO AND CAN PERSIST UP TO 7 MONTHS FOLLOWING RESOLUTION OF SYMPTOMS. Gastroenterology, 2021, 160, S-159.	1.3	1
26	ls statin preventing cancer in HIV-1 infected individuals? An inappropriate methodology is a more likely explanation. Aids, 2015, 29, 857-859.	2.2	0
27	Characteristics of Patients Who Acquired Human Immunodeficiency Virus (HIV) Infection Despite Accessing Healthcare: Implications for HIV Prevention Strategies. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
28	Fr137 FIRST HIGH DIMENSIONAL EXAMINATION OF INTESTINAL BIOPSIES IN PATIENTS WITH COVID-19. Gastroenterology, 2021, 160, S-234-S-235.	1.3	0
29	Fr492 SIGNIFICANTLY REDUCED MORTALITY IN COVID-19 PATIENTS WITH GASTROINTESTINAL MANIFESTATIONS. Gastroenterology, 2021, 160, S-330.	1.3	Ο